Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

46.25 +0.31 (+0.67%)

Official Closing Price Updated: 4:10 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

82 83 Next >

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

March 18, 2024

From Bristol Myers Squibb

Via Business Wire

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

March 15, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy ↗

March 15, 2024

FDA grants accelerated approval to Bristol Myers Squibb's Breyanzi, a CAR T cell therapy for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two prior lines of...

Via Benzinga

Why NYSE:BMY is a Top Pick for Dividend Investors. ↗

March 12, 2024

Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) a Good Fit for Dividend Investing?

Via Chartmill

Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb ↗

March 11, 2024

Via Benzinga

Bristol-Myers Squibb's Options Frenzy: What You Need to Know ↗

March 04, 2024

Via Benzinga

What's Going On With Cancer Focused-Geron Stock On Friday? ↗

March 15, 2024

Geron sees lower share price with high volume. FDA committee votes favorably on imetelstat for transfusion-dependent anemia in adult MDS patients. June 16, 2024, set as FDA target action date....

Via Benzinga

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

March 14, 2024

From Bristol Myers Squibb

Via Business Wire

FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers ↗

March 13, 2024

Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...

Via Benzinga

A Closer Look at Bristol-Myers Squibb's Options Market Dynamics ↗

February 22, 2024

Via Benzinga

How Is The Market Feeling About Bristol-Myers Squibb? ↗

February 21, 2024

Via Benzinga

Be A Smart Investor – Don’t Hold On For Dear Life ↗

March 13, 2024

You have to give credit where it’s due. The bulls have been relentless for almost 18 months, but certainly over the past 5 months.

Via Talk Markets

Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024

March 11, 2024

From Bristol Myers Squibb

Via Business Wire

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

March 07, 2024

From Bristol Myers Squibb

Via Business Wire

Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 ↗

March 07, 2024

Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...

Via Benzinga

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

March 06, 2024

From Bristol Myers Squibb

Via Business Wire

Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town ↗

March 06, 2024

Discover must-have stocks for wealth for every investor, from healthcare and communication giants to financial and industrial sectors.

Via InvestorPlace

Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic ↗

March 05, 2024

As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 04, 2024

Via Benzinga

Bristol Myers Squibb Announces Dividend

March 01, 2024

From Bristol Myers Squibb

Via Business Wire

The Hot List: 3 AI Stocks Worth Buying on Weakness ↗

March 01, 2024

Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.

Via InvestorPlace

Topics Artificial Intelligence

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

February 29, 2024

From Bristol Myers Squibb

Via Business Wire

Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss ↗

February 28, 2024

Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D...

Via Benzinga

Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference

February 26, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

February 26, 2024

From Bristol Myers Squibb

Via Business Wire

3 Highly Rated Biotech Stocks to Buy for 300% Gains ↗

February 26, 2024

Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.

Via InvestorPlace

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

February 23, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

February 23, 2024

From Bristol Myers Squibb

Via Business Wire

Mental Health Mavericks: 3 Stocks Changing the Game ↗

February 21, 2024

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Via InvestorPlace

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

82 83 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today